70P A retrospective real-world study of anlotinib plus PD-1 inhibitors in advanced esophageal squamous cell carcinoma (ESCC) previously treated with immune checkpoint inhibitors (ICIs). (December 2022) - Liu, J.; Zhu, X.; Cheng, Y.; Li, H.; Ma, X.; Fu, X.